PRNewswire: May 13, 2017 – KANSAS CITY, KS, U.S.A. – Cingulate Therapeutics, LLC, a privately held biopharmaceutical company focused on the development of new and innovative products for the treatment of attention deficit/hyperactivity disorder (ADHD), is proud to announce its transition to a…
